Announced Date: 2025-08-11 (August 11, 2025)
Asset Name: XH-S004
Licensor: Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (“Fosun Pharma”; stock code: 600196.SH, 02196.HK) (Headquarter，Shanghai, China)
Licensee (Buyer): Licensee (Buyer): Expedition Therapeutics Inc. (Expedition, USA)
Asset Target: Oral DPP-1 inhibitor
Asset Modality: Small Molecule
Current Stage: China phase II、phase Ib
Scope of Authority:
Forsun has granted Expedition an exclusive license to develop, manufacture, and commercialize XH-S004 outside Great China
Deal Detail:
Upfront payment of $17 million
Milestone payments up to $102 million
(if certain development, regulatory milestones are achieved)
Milestone payments up to $525 million(if certain commercial milestones are achieved)
Other fee
Total up to 645 million
Link:
